Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(02)07430-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
BMC Cancer
January 2025
Centre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.
Background: Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2, causing constitutive activation of the kinase and activation of downstream signalling.
View Article and Find Full Text PDFPegylated interferon: the who, why, and how.
Hematology Am Soc Hematol Educ Program
December 2024
Hopital Saint-Louis, Paris Cité University, Inserm CIC 1427, Paris, France.
Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms. Indeed, IFN-α has been used for decades across all myeloproliferative neoplasms, but only recently a new form, ropegIFN-α2b, was approved to treat patients with polycythemia vera.
View Article and Find Full Text PDFHepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates.
Pathol Res Pract
November 2024
Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy. Electronic address:
Article Synopsis
- Hepatoid thymic carcinoma (HTC) is a rare tumor that looks similar to liver cancer, specifically found in the thymus gland, and a new case has been identified in a 40-year-old man with polycythemia vera.
- This case involved advanced analysis of the tumor's molecular profile, noting the presence of various proteins through immunohistochemistry and significant mutations identified via whole exome sequencing.
- The study suggests that HTC may represent an evolutionary shift in tumor characteristics, combining features of both thymic carcinoma and hepatoid tumors, indicated by the unique mutation patterns found in the cells.
Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis.
BMC Infect Dis
October 2024
Department of infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital, of Wenzhou Medical University, Wenzhou, China.
Background: The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was still in debate.
Methods: We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022.
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.
Br J Haematol
December 2024
CRIMM, Azienda Ospedaliera Universitaria Careggi, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy.
Article Synopsis
- The study compared the effects of Ropeginterferon alfa-2b (Ropeg) and phlebotomy-only (Phl-O) on the neutrophil-to-lymphocyte ratio (NLR) in 126 patients with low-risk polycythemia vera (PV).
- Results showed that Ropeg significantly reduced NLR, driven mainly by a drop in neutrophils, and this reduction correlated with better symptom management and lower JAK2 variant allele frequency.
- The findings suggest that monitoring NLR could be a useful tool for guiding Ropeg treatment in early-stage low-risk PV patients, particularly when distinguishing between treatment responders and non-responders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!